Tag Archives: mygn

Myriad Genetics Dives, But Analysts Upbeat On MyRisk

Shares of genetic-testing company Myriad Genetics (MYGN) tumbled Wednesday after the company’s guidance missed estimates late Tuesday, though analyst reaction was more sanguine. Myriad Genetics stock was down 10% in afternoon trading in the stock market today, near 35. Leerink analyst Dan Leonard raised his price target to 38 from 35, writing in his note Wednesday that though the near-term outlook was soft, the uptake of the new MyRisk hereditary

Myriad Genetics Guidance Disappoints, Q4 Edges Views

Gene-tester Myriad Genetics modestly beat fiscal Q4 estimates late Tuesday, but EPS guidance below consensus sent the stock falling 5% in after-hours trading. Revenue for the quarter that ended June 30 rose 8.4% over the year-earlier quarter to $188.8 million, less than $1 million above analysts’ average estimate. Profit declined 9.5% to 48 cents a share, beating consensus by 2 cents. Myriad Genetics (MYGN) guided fiscal 2015 revenue at $800

Myriad Genetics’ Earnings Face ‘Angelina Jolie’ Comps

Gene-testing company Myriad Genetics (MYGN) will report fiscal Q4 earnings after the close Tuesday that Wall Street expects will show tougher year-over-year comparisons for the high-rated stock. Analysts’ consensus calls for 8% sales growth to $187.7 million, the slowest pace since late 2010. Profit is expected to shrink 13% to 46 cents a share. A year ago, Myriad was riding high on what observers dubbed “the Angelina Jolie effect,” after the